Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treating a hematological cancer in a subject. In some embodiments, the method comprises determining the presence or absence of at least one mutation in one or more genes encoding a spliceosome protein in sample nucleic acids from the subject; and administering onvansertib and decitabine to the subject, if the at least one mutation in one or more genes encoding a spliceosome protein is determined to be present in the sample nucleic acids, thereby reducing or inhibiting progression of the hematological cancer in the subject.

Abstract: Certain molecular characteristics of cancer cells or tumors can be indicative of their sensitivity to various combination therapies. The cancer cells or tumors exhibiting such molecular profiles, such as upregulation of genes associated with mitosis or meiosis, can be sensitive to additive and more than additive effects of combination therapies. Methods for identifying, selecting, and/or treating cancer patients whose cancer is amenable to combination therapies including an antiandrogen or androgen antagonist in combination with a Plk inhibitor are disclosed. Administration of the combination of the active agents can reduce cancer cell proliferation or viability and/or tumor burden in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone.